Меню
Набор скоро начнётся NCT07381205

Assessing the Incidence of Transplant Associated Thrombotic Microangiopathy (TA-TMA) in Adult Patients Undergoing Allogeneic Stem Cell Transplant (SCT)

— Наблюдательное Transplant Associated Microangiopathy TAM Transplant Complication

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
Это наблюдательное исследование: исследуемое лечение участникам по протоколу не назначают.
Кому может быть актуально
Состояния в реестре: Transplant Associated Microangiopathy TAM, Transplant Complication. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
США
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

Prospective Evaluation of Transplant Associated Thrombotic Microangiopathy (TA-TMA) Markers in a High-risk Cohort of Adults Undergoing Allogeneic Stem Cell Transplantation (SCT)

Обзор

The goal of this observational study is to learn about the incidence of Transplant Associated Thrombotich Microangiopathy (TA-TMA), which is a known but underreported complication of Allogeneic Stem Cell Transplant (SCT). The main question it aims to answer is: What is the incidence of TA-TMA in adults undergoing SCT? How does TA-TMA diagnosis impact survival and other outcomes? Patients undergoing SCT will be eligible for this study, which will consist of collection of biological samples and standard clinical follow up.

Подробное описание

This will be a prospective non-interventional study that will include patients undergoing allogeneic stem cell transplant (SCT) deemed to be at high risk for developing Transplant Associated Thrombotic Microangiopathy (TA-TMA). All patients will have prospective biospecimens collected per study schedule starting prior to SCT. Biospecimens will be collected for use in translational testing and sent to Viracor for commercial testing. Results of commercial testing will be made available to treating physicians. Diagnosis of TA-TMA will be made based on clinical and laboratory values according to existing consensus guidelines, however, therapeutic decisions will be left up to the treating clinical team. Patients will be followed up for clinical outcomes.

Первичные конечные точки

  • Primary Objectives [Срок оценки: From enrollment until 1 year post SCT]
  • Co-Primary Objective [Срок оценки: From enrollment until 1 year post SCT]
Вторичные конечные точки (4)
  • Secondary Objectives [Срок оценки: From enrollment until 1 year post SCT]
  • Secondary Objective [Срок оценки: From enrollment until 1 year post SCT]
  • Secondary Objective [Срок оценки: From enrollment until 1 year post SCT]
  • Secondary Objective [Срок оценки: From enrollment until 1 year post SCT]

Критерии участия

Критерии включения

  • Inclusion Criteria
  • Adult male or female, age ≥18
  • Undergoing allogeneic SCT at UAB for any indication and any donor source.
  • For patients in cohort 1: Patients deemed high-risk for developing high-risk TA-TMA as stated by any of the following criteria\*:
  • BMI > 35\[42\]
  • Mismatched donor (either Haploidentical or Mismatched Unrelated donor)\[18, 29\]
  • Non-Malignant Transplant Indication (Severe Aplastic Anemia or Sickle Cell Disease)\[18, 43\]
  • Acute Lymphoblastic Leukemia (any kind)\[18, 31\]
  • African American, Hispanic, Asian or Native American Ethnicity \[44\]
  • Myeloablative Conditioning Regimen\[18\]
  • Pre-Existing Renal Disease\*\* (defined as any of the following: 24 Hr Creatinine Clearance <60, baseline serum creatinine > 1.2, 24 hr proteinuria >150mg or random spot urine Protein Creatinine ratio > 150mg/g)\[20, 45\]
  • TBI-containing conditioning regimen >400cGy \[46\]
  • Prior Autologous or Allogeneic SCT\[45\]
  • \*Some of these criteria have been adapted from pediatric literature due to a higher number of publications in that setting and in cases where the adult data is lacking or contradictory.
  • \*\*Proteinuria thresholds are obtained from KDIGO guidelines and include moderate and severe levels of proteinuria\[47\].
  • Females of childbearing potential must have a negative urine or serum pregnancy test prior to enrollment.
  • For patients in cohort 2: Patients who develop GVHD with any of the following characteristics and were not included in cohort 1
  • Grade III-IV aGVHD, or SR-aGVHD of any grade, whichever occurs first
  • Moderate to Severe cGVHD or SR-cGVHD of any grade, whichever occurs first
  • For patients in cohort 3: Patients included in either cohort 1 or 2 who are diagnosed with TA-TMA and receive eculizumab

Критерии исключения

  • Exclusion Criteria
  • Any other active malignancy requiring treatment or with expected survival ≤1 year.
  • Patients with psychiatric illness or social situations that would limit compliance with the study requirements.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения
Когортное

Центры проведения

США · 1 центр
  • O'Neal Comprehensive Cancer Center at UAB — Birmingham

Идентификаторы

NCT: NCT07381205 · IRB-30005854 (2537) · Robert A. Winn CDA

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗